HELSINKI, FINLAND (OCTOBER 9, 2019) – MEGIN is pleased to announce the sale of our fourth-generation technology, the TRIUX™ neo, to three internationally renowned neuroscience facilities.

 

We are looking forward to working with the MRC Cognition and Brain Sciences Unit at the University of Cambridge, the Shanghai Mental Health Center in China, and the Veterans Affairs West Haven Medical Center, in Connecticut.  By partnering with these renowned neuroscience facilities, we are excited to advance MEG technology and expand its use worldwide.

 

“This is a significant milestone for MEGIN and the entire MEG industry,” said Gordon Baltzer, CEO of Croton Healthcare, parent company of MEGIN. “In a rapidly expanding neurosciences industry, we are seeing greater demand for functional brain imaging technologies and more particularly for MEG, due to its ability to record brain function in real time.  As we continue to develop additional tools that allow for greater clinical utility for the TRIUX neo, we expect to see MEG technology being utilized more frequently by leading academic and clinical neuroscience centers.”

 

TRIUX neo is a highly sensitive technology that can accurately detect and localize neural events that are generated in the brain with millimeter accuracy and millisecond resolution. TRIUX neo provides access to all patients, regardless of size or age, for the most precise information currently available on the market today for functional brain imaging.

 

MEG is used by neurosurgeons to support surgical procedures for epilepsy and brain tumours. It is also currently being used in research to address some of the most challenging neurological disorders that impact global public health, including Traumatic Brain Injury (TBI), Post-Traumatic Stress Disorder (PTSD), Alzheimer’s, and Dementia.

 

 “We are excited for the new future of MEG which will allow expanded patient access, providing the clinical community the potential to create a new standard of care,” said Baltzer.

 

About MEGIN

 

MEGIN, a Croton Healthcare company, is a neuroscience technology company based in Helsinki, Finland.  The company is focused on developing innovative solutions for functional brain imaging for the presurgical evaluation of epilepsy, brain tumours or other lesions of the brain.  For over 30 years, MEGIN has been the global leader in magnetoencephalography (MEG) technology, and launched in 2018 the fourth-generation MEG system, TRIUX™ neo. The TRIUX neo provides a non-invasive, real time view of patient specific neural activity with millimeter accuracy and millisecond resolution and provides the most precise information currently available on the market today.

 

Media Contact

info@megin.fi